// App-Quantinova.ai

: The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Researchers

Presenter

  • Lennart Lenk

Principal Investigators

  • Irene Baccelli

  • Dorothee Winterberg

  • Anna Dietterle

  • Frédérique Corallo

  • Julien Taurelle

  • Emma Narbeburu

  • Anna Laqua

  • Beat Bornhauser

  • Jean-Pierre Bourquin

  • Fotini Vogiatzi

  • Martin Schrappe

  • Gunnar Cario

  • Monika Bruggemann

  • Nicolas Poirier

  • Denis Martin Schewe

Medical Centers

  • OSE Immunotherapeutics, Nantes, France

  • Department of Pediatrics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

  • Department of Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany

  • Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany

  • Department of Pediatric Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland

  • University Children's Hospital Zürich, Zürich, Switzerland

Locations

  • France

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Sjogren's syndrome

  • Ulcerative colitis

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • PEG-asparaginase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Vincristine

  • Interleukin

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • pivotal

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved